Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jul 10:11:1159-1169.
doi: 10.2147/PPA.S130276. eCollection 2017.

Evaluating patient preference and satisfaction for human immunodeficiency virus therapy in France

Sylvie Brégigeon-Ronot  1 , Antoine Cheret  2   3 , André Cabié  4 , Thierry Prazuck  5 , Alain Volny-Anne  6 , Shehzad Ali  7 , Catherine Bottomley  7 , Laurent Finkielsztejn  8 , Caroline Philippe  9 , Jean-Jacques Parienti  10   11   12
Affiliations

Evaluating patient preference and satisfaction for human immunodeficiency virus therapy in France

Sylvie Brégigeon-Ronot et al. Patient Prefer Adherence. .

Abstract

Objectives: The objectives were 1) to elicit relative preferences for attributes of antiretroviral therapies (ART) in people living with HIV (PLWH) and 2) to explore satisfaction and adherence with current ART.

Patients and methods: We conducted a multicenter cross-sectional study, consecutively enrolling PLWH receiving an ART. The quantitative part estimated the strength of preference for different attributes using an online discrete choice experiment (DCE). DCE data were analyzed using a mixed logit regression model. Qualitative data were collected through individual interviews. A preliminary coding framework was developed which was then further refined and applied during thematic analysis of factors influencing satisfaction and adherence.

Results: A total of 101 PLWH took part in the quantitative part and 31 in the qualitative part. Over 90% had an undetectable viral load. Quantitative data revealed a strong preference for a treatment with limited drug-drug interactions, diarrhea and long-term health problems (P<0.0001), and that did not need to be taken on an empty stomach (P<0.0001). Patients also preferred to avoid problems associated with treatment failure (P<0.0001) or one that left them with a higher viral load after the first weeks of treatment (P=0.044). Differences in CD4 cell count, and pills that must be taken with food were not significant drivers of treatment choice. The strength of these attributes was reflected in the qualitative data, highlighting the importance patients place on treatment efficacy, and also suggesting that some of these attributes may impact adherence. Many factors influencing adherence and satisfaction with treatment were identified, including pill size, worry about sexual transmission and impact on social life.

Conclusion: Most of the attributes included in this survey were important to participants when choosing an ART, in particular those related to quality of life, and these should be taken into account in order to optimize adherence and satisfaction.

Keywords: ARV treatments; HIV infection; adherence; antiretroviral therapy; preference elicitation; satisfaction.

PubMed Disclaimer

Conflict of interest statement

Disclosure S Brégigeon-Ronot: Gilead, Janssen, ViiV Healthcare. A Cheret: ViiV Healthcare. A Cabié: Gilead, Janssen, ViiV Healthcare. T Prazuck: Gilead, ViiV Healthcare, Janssen. A Volny-Anne: none. S Ali: employed by Icon, contract research organization at time of study. C Bottomley: employed by Icon, contract research organization at time of study. L Finkielsztejn: employed by ViiV Healthcare. C Philippe: employed by Qualees, contract research organization. JJ Parienti: Gilead science, Janssen Pharmaceuticals, ViiV Healthcare, MSD. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Discrete choice experiment results. Abbreviations: ARV, antiretroviral drug; CI, confidence intervals; NS, not significant.
See this image and copyright information in PMC

References

    1. Panel on Antiretroviral Guidelines for Adults and Adolescents Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. [Accessed April 11, 2016]. Available from: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
    1. Morlat P. Prise en charge médicale des personnes vivant avec le VIH. Recommandations du groupe d’experts – Rapport 2013. Sous la direction du Pr Philippe Morlat et sous l’égide du CNS et de l’ANRS [Medical care of people living with HIV. Expert group recommendations – 2013 report] [Accessed April 11, 2016]. Available from: http://www.sante.gouv.fr/IMG/pdf/Rapport_Morlat_2013_Mise_en_ligne.pdf. French.
    1. Delfraissy JF. Prise en charge des personnes infectées par le VIH: Recommandations du groupe d’experts – 2002 [Medical care of people living with HIV. Expert group recommendations – 2002 report] [Accessed April 11, 2016]. Available from: http://www.ladocumentationfrancaise.fr/var/storage/rapports-publics/0340.... French.
    1. Turner BJ. Adherence to antiretroviral therapy by human immunodeficiency virus-infected patients. J Infect Dis. 2002;185(Suppl 2):S143–S151. - PubMed
    1. Ammassari A, Murri R, Pezzotti P, et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr. 2001;28(5):445–449. - PubMed